Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)

Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)

Abstract Background The Neo-REGATTA study evaluated the effectiveness and safety of Docetaxel, oxaliplatin, and S-1 (DOS regimen) followed by radical resection vs. chemotherapy in advanced gastric adenocarcinoma patients with single non-curable factor. Methods This cohort study prospectively enrolle...

Full description

Bibliographic Details
Main Authors: Yuehong Cui, Yiyi Yu, Song Zheng, Jie’er Ying, Yi’an Du, Yan Wang, Xuefei Wang, Zhenbin Shen, Fenglin Liu, Minzhi Lv, Yihong Sun, Tianshu Liu
Format: Article
Language:English
Published: BMC 2023-04-01
Series:BMC Cancer
Subjects:
Stomach neoplasms
Adenocarcinoma
Oligometastasis
Radical resection
Perioperative chemotherapy
Efficacy
Online Access:https://doi.org/10.1186/s12885-023-10773-x

Internet

https://doi.org/10.1186/s12885-023-10773-x

Similar Items